{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T15:50:25Z","timestamp":1753890625157,"version":"3.41.2"},"reference-count":37,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,4,25]],"date-time":"2023-04-25T00:00:00Z","timestamp":1682380800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Recently, the survival rate of patients with cancer has improved annually due to advancements in cancer diagnosis and treatment technologies. Meanwhile, late-onset complications associated with cancer treatment significantly affect survival and quality of life. However, different from pediatric cancer survivors, there is no unified view on the follow-up of late complications in elderly cancer survivors. We reported a case of congestive heart failure as a late-onset complication of doxorubicin (DXR) in an elderly cancer survivor.<\/jats:p><\/jats:sec><jats:sec><jats:title>Case report<\/jats:title><jats:p>The patient is an 80-year-old woman with hypertension and chronic renal failure. She received six cycles of chemotherapy for Hodgkin's lymphoma that started in January 201X-2. The total dose of DXR was 300\u2005mg\/m<jats:sup>2<\/jats:sup>, and a transthoracic echocardiogram (TTE) performed in October 201X-2, showed good left ventricular wall motion (LVWM). In April 201X, she suddenly developed dyspnea. Upon arrival at the hospital, a physical examination revealed orthopnea, tachycardia, and leg edema. A chest radiograph showed cardiac enlargement and pleural effusion. A TTE showed diffusely reduced LVWM and a left ventricular ejection fraction in the 20% range. After close examination, the patient was diagnosed with congestive heart failure due to late-onset DXR-induced cardiomyopathy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Late-onset DXR-induced cardiotoxicity is considered high-risk from 250\u2005mg\/m<jats:sup>2<\/jats:sup> or higher. Elderly cancer survivors are at higher risk of cardiotoxicity than non-elderly cancer survivors and may require closer follow-up.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fcvm.2023.1124276","type":"journal-article","created":{"date-parts":[[2023,4,25]],"date-time":"2023-04-25T04:38:23Z","timestamp":1682397503000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Late-onset doxorubicin-induced congestive heart failure in an elderly cancer survivor: A case report"],"prefix":"10.3389","volume":"10","author":[{"given":"Hirotaka","family":"Suto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makiko","family":"Suto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yumiko","family":"Inui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsuo","family":"Okamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,4,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21708","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1056\/NEJMsr1905447","article-title":"Epidemiologic signatures in cancer","volume":"381","author":"Welch","year":"2019","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.1253\/circj.CJ-20-0467","article-title":"Cancer therapeutics-related cardiac dysfunction\u2014insights from bench and bedside of onco-cardiology","volume":"84","author":"Kadowaki","year":"2020","journal-title":"Circ J"},{"key":"B4","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1007\/s12012-022-09721-1","article-title":"Doxorubicin-induced cardiotoxicity: an overview on pre-clinical therapeutic approaches","volume":"22","author":"Sheibani","year":"2022","journal-title":"Cardiovasc Toxicol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"2869","DOI":"10.1002\/cncr.11407","article-title":"Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials","volume":"97","author":"Swain","year":"2003","journal-title":"Cancer"},{"key":"B6","doi-asserted-by":"publisher","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","article-title":"2022 Esc guidelines on cardio-oncology developed in collaboration with the European hematology association (eha), the European society for therapeutic radiology and oncology (ESTRO) and the international cardio-oncology society (IC-OS)","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur Heart J"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1200\/JCO.18.01764","article-title":"Therapy-related cardiac risk in childhood cancer survivors: an analysis of the childhood cancer survivor study","volume":"37","author":"Bates","year":"2019","journal-title":"J Clin Oncol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"2629","DOI":"10.1200\/JCO.2005.12.121","article-title":"Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia","volume":"23","author":"Lipshultz","year":"2005","journal-title":"J Clin Oncol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1056\/NEJMoa035153","article-title":"The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia","volume":"351","author":"Lipshultz","year":"2004","journal-title":"N Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","first-page":"Jco2202423","DOI":"10.1200\/JCO.22.02423","article-title":"Dexrazoxane and long-term heart function in survivors of childhood cancer","author":"Chow","year":"2023","journal-title":"J Clin Oncol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1016\/j.echo.2014.07.012","article-title":"Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American society of echocardiography and the European association of cardiovascular imaging","volume":"27","author":"Plana","year":"2014","journal-title":"J Am Soc Echocardiogr"},{"key":"B12","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1200\/JCO.2016.70.5400","article-title":"Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: american society of clinical oncology clinical practice guideline","volume":"35","author":"Armenian","year":"2017","journal-title":"J Clin Oncol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"2135","DOI":"10.1200\/JCO.2017.76.3920","article-title":"Cardiovascular disease in survivors of childhood cancer: insights into epidemiology, pathophysiology, and prevention","volume":"36","author":"Armenian","year":"2018","journal-title":"J Clin Oncol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.annonc.2019.10.023","article-title":"Management of cardiac disease in cancer patients throughout oncological treatment: esmo consensus recommendations","volume":"31","author":"Curigliano","year":"2020","journal-title":"Ann Oncol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"S129","DOI":"10.1097\/01.CCM.0000296274.51933.4C","article-title":"Practical recommendations for prehospital and early in-hospital management of patients presenting with acute heart failure syndromes","volume":"36","author":"Mebazaa","year":"2008","journal-title":"Crit Care Med"},{"key":"B16","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1056\/NEJMoa2206125","article-title":"Overall survival with brentuximab vedotin in stage III or IV hodgkin\u2019s lymphoma","volume":"387","author":"Ansell","year":"2022","journal-title":"N Engl J Med"},{"key":"B17","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1056\/NEJMoa2115304","article-title":"Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma","volume":"386","author":"Tilly","year":"2022","journal-title":"N Engl J Med"},{"key":"B18","doi-asserted-by":"publisher","first-page":"2621","DOI":"10.1200\/JCO.2018.79.2028","article-title":"Double-blind phase III trial of adjuvant chemotherapy with and without bevacizumab in patients with lymph node-positive and high-risk lymph node-negative breast cancer (E5103)","volume":"36","author":"Miller","year":"2018","journal-title":"J Clin Oncol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1001\/jamaoncol.2019.0001","article-title":"Effect of taxane plus platinum regimens vs doxorubicin plus cisplatin as adjuvant chemotherapy for endometrial cancer at a high risk of progression: a randomized clinical trial","volume":"5","author":"Nomura","year":"2019","journal-title":"JAMA Oncol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1200\/JCO.2010.33.4730","article-title":"High risk of symptomatic cardiac events in childhood cancer survivors","volume":"30","author":"van der Pal","year":"2012","journal-title":"J Clin Oncol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1200\/JCO.2013.51.1055","article-title":"Aging and risk of severe, disabling, life-threatening, and fatal events in the childhood cancer survivor study","volume":"32","author":"Armstrong","year":"2014","journal-title":"J Clin Oncol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"3889","DOI":"10.1093\/eurheartj\/ehz766","article-title":"A population-based study of cardiovascular disease mortality risk in US cancer patients","volume":"40","author":"Sturgeon","year":"2019","journal-title":"Eur Heart J"},{"key":"B23","doi-asserted-by":"publisher","first-page":"R64","DOI":"10.1186\/bcr2901","article-title":"Cardiovascular disease competes with breast cancer as the leading cause of death for older females diagnosed with breast cancer: a retrospective cohort study","volume":"13","author":"Patnaik","year":"2011","journal-title":"Breast Cancer Res"},{"key":"B24","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1172\/JCI72931","article-title":"Cardiotoxicity of doxorubicin is mediated through mitochondrial iron accumulation","volume":"124","author":"Ichikawa","year":"2014","journal-title":"J Clin Invest"},{"key":"B25","doi-asserted-by":"publisher","first-page":"3861","DOI":"10.1158\/1078-0432.CCR-20-4592","article-title":"Prospective evaluation of doxorubicin cardiotoxicity in patients with advanced soft-tissue sarcoma treated in the announce phase III randomized trial","volume":"27","author":"Jones","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1038\/nm.2919","article-title":"Identification of the molecular basis of doxorubicin-induced cardiotoxicity","volume":"18","author":"Zhang","year":"2012","journal-title":"Nat Med"},{"key":"B27","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/clpt.2013.201","article-title":"Topoisomerase 2\u03b2: a promising molecular target for primary prevention of anthracycline-induced cardiotoxicity","volume":"95","author":"Vejpongsa","year":"2014","journal-title":"Clin Pharmacol Ther"},{"key":"B28","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1038\/nrcardio.2015.65","article-title":"Cardiotoxicity of anticancer treatments","volume":"12","author":"Ewer","year":"2015","journal-title":"Nat Rev Cardiol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"100994","DOI":"10.1016\/j.cpcardiol.2021.100994","article-title":"Ac-mode of chemotherapy as a trigger of cardiac syndrome x: a case study","volume":"47","author":"Avagimyan","year":"2022","journal-title":"Curr Probl Cardiol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1002\/ejhf.654","article-title":"2016 Esc position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the esc committee for practice guidelines: the task force for cancer treatments and cardiovascular toxicity of the European society of cardiology (esc)","volume":"19","author":"Zamorano","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"B31","doi-asserted-by":"publisher","first-page":"e123","DOI":"10.1016\/S1470-2045(14)70409-7","article-title":"Recommendations for cardiomyopathy surveillance for survivors of childhood cancer: a report from the international late effects of childhood cancer guideline harmonization group","volume":"16","author":"Armenian","year":"2015","journal-title":"Lancet Oncol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/j.canep.2014.07.005","article-title":"Estimated life expectancy and risk of death from cancer by quartiles in the older Japanese population: 2010 vital statistics","volume":"38","author":"Iwamoto","year":"2014","journal-title":"Cancer Epidemiol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.jacc.2009.03.095","article-title":"Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy","volume":"55","author":"Cardinale","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1161\/CIRCULATIONAHA.114.013777","article-title":"Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy","volume":"131","author":"Cardinale","year":"2015","journal-title":"Circulation"},{"key":"B35","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1007\/s00392-018-1386-0","article-title":"Recovery from left ventricular dysfunction was associated with the early introduction of heart failure medical treatment in cancer patients with anthracycline-induced cardiotoxicity","volume":"108","author":"Ohtani","year":"2019","journal-title":"Clin Res Cardiol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1200\/JCO.2010.34.3467","article-title":"Pharmacogenomic prediction of anthracycline-induced cardiotoxicity in children","volume":"30","author":"Visscher","year":"2012","journal-title":"J Clin Oncol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"26","DOI":"10.3389\/fcvm.2020.00026","article-title":"Cardiotoxicity of anthracyclines","volume":"7","author":"Cardinale","year":"2020","journal-title":"Front Cardiovasc Med"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2023.1124276\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,25]],"date-time":"2023-04-25T04:38:35Z","timestamp":1682397515000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2023.1124276\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,25]]},"references-count":37,"alternative-id":["10.3389\/fcvm.2023.1124276"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2023.1124276","relation":{},"ISSN":["2297-055X"],"issn-type":[{"type":"electronic","value":"2297-055X"}],"subject":[],"published":{"date-parts":[[2023,4,25]]},"article-number":"1124276"}}